The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...

THE sequence of hemoglobinuria followed by oliguria and anuria is well known. The observations reported below are especially concerned with the medical management of the anuric patient and with the ...

CHRONIC lymphocytic leukemia and malignant lymphomas of the lymphocytic and follicular types may be relatively prolonged, benign diseases. They are inevitably fatal, however, and the final years are ...

red blood cells The FDA has granted Priority Review for the Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, a rare ...

Is This Intravascular Immune Hemolysis? The term "immune" implies that the hemolysis is antibody-related. Because the type and antibody screen and the DAT were negative, the hemolysis was probably not ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...

Researchers have discovered how hemolysis causes infections, and have found a new means to prevent it, paving the way to new treatment possibilities. For decades, iron has been considered the prime ...

Hemolysis is the #1 source of preanalytical error and can impact potassium results—potentially leading to inappropriate or delayed patient treatment, unnecessary ...

Hemolysis is a common pre-analytical variable that can lead to inaccurate results, specimen rejection, and specimen recollection in the clinical laboratory. Hemolysis is most often an in vitro ...

Physical/chemical causes. These causes of hemolysis are most often secondary to improper handling of blood products. Reasons include inadvertent heating or freezing with subsequent thawing of the red ...